NeoGenomics Q2 revenue up 18% to $147M; net loss narrows 31% to $24M

NEOGENOMICS INC

Revenue of $147M (+18% YoY); Clinical Services $123M (+17%), Advanced Diagnostics $24M (+22%).
Net loss decreased 31% to $24M; Adjusted EBITDA improved 87% to -$2M from -$16M.
Adjusted Net Loss $7M vs $20M in prior year; cash and marketable securities $409M.
FY 2023 guidance raised: revenue $565-575M, net loss $(107)-(100)M, Adjusted EBITDA $(13)-(10)M.
Pharma Services segment rebranded as Advanced Diagnostics; restructuring charges included in Q2.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEOGENOMICS INC reported second fiscal quarter of 2023 results: revenue $147 million, net income $24 million. Guidance raised.

Period: second fiscal quarter of 2023
Revenue: $147 million
Net income: $24 million
Guidance: raised
Result: reported results

Exact text from the filing

as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Fort Myers, Florida (August 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its second-quarter results

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NEOGENOMICS INC filing history →

Source: SEC EDGAR

accession 0001077183-23-000099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.